PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Get Free Report) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 14,700 shares, a decrease of 40.7% from the June 30th total of 24,800 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 17,200 shares, the short-interest ratio is currently 0.9 days.
Institutional Investors Weigh In On PharmaCyte Biotech
A hedge fund recently raised its stake in PharmaCyte Biotech stock. K2 Principal Fund L.P. raised its position in shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Free Report) by 17.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 304,613 shares of the company’s stock after buying an additional 46,132 shares during the period. K2 Principal Fund L.P. owned about 3.53% of PharmaCyte Biotech worth $655,000 at the end of the most recent reporting period. 34.24% of the stock is currently owned by institutional investors.
PharmaCyte Biotech Stock Down 1.9 %
Shares of PharmaCyte Biotech stock traded down $0.04 during trading on Friday, reaching $1.98. The company’s stock had a trading volume of 1,735 shares, compared to its average volume of 21,253. PharmaCyte Biotech has a 52-week low of $1.76 and a 52-week high of $2.82. The company has a market cap of $16.74 million, a price-to-earnings ratio of -1.65 and a beta of -0.19. The firm’s 50-day moving average is $2.07 and its two-hundred day moving average is $2.14.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.
Read More
- Five stocks we like better than PharmaCyte Biotech
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Stock Dividend Cuts Happen Are You Ready?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.